SPT Lab
@spt_lab
Followers
239
Following
56
Media
7
Statuses
54
Laboratory of Dr. Shari Pilon-Thomas and Dr. John Mullinax Moffitt Cancer Center | Tumor Infiltrating Lymphocyte (TIL) Therapy
Tampa, FL
Joined January 2022
RT @CancerBiol_PhD: šš· Congratulations to Sarah Bazargan, PhD! Sarah successfully defended her dissertation last week! She looked at how taā¦.
0
2
0
RT @RejniakLab: Another great HIP-IMO program, this year led by @ReneeBradyPhD with 15 amazing presentations, including Eros in collaboratiā¦.
0
2
0
RT @JadChahoud: ā¼ļøšØGreat and insightful commentary on TIL therapy giving new hope for pts w solid cancers @ASCO by our @MoffittNews TIL leaā¦.
0
2
0
Here are even more of their smiling faces and fantastic posters! We are so proud of our lab members and the great work that they do.
0
0
4
Last week, many of our lab members presented at the #MoffittSymposium! Thank you to everyone who came out to support!
1
0
4
As the voting deadline approaches for the #SITC elections, we wanted to share some more information about our very own Dr. Shari Pilon-Thomas who is nominated for the ā¦@sitcancerā© At-Large Director! Get your votes in now!
1
1
2
RT @MoffittNews: Join Oluwaseyi Oluwatola of @spt_lab at #AAI2024 as she presents on the functional role of KLRG1+ Tregs in non-small cellā¦.
0
1
0
RT @MoffittNews: Congratulations to our Shari Pilon-Thomas, PhD, (@spt_lab) for being nominated as a @sitcancer At-Large Director!. Learn mā¦.
0
7
0
RT @MoffittNews: We are thrilled that our Shari Pilon-Thomas, PhD, (@spt_lab) has been nominated as a @sitcancer At-Large Director!.
0
2
0
We are excited and rooting for our very own Dr. Shari Pilon-Thomas! Go vote!.
The #SITC election starts on Thursday! The three At-Large Directors who receive the plurality of votes will begin three-year terms in 2025. Read the biographies and platform statements of this yearās candidates at
0
3
7
RT @JohnEMullinaxMD: Sharing my support for @spt_lab who has been a tremendous mentor to me and so many others. She is a prolific collaborā¦.
0
2
0
After a posting hiatus, we are back and happy to share our excitement over the FDA approval of Tumor-Infiltrating Lymphocytes for the treatment of advanced melanoma! .
moffitt.org
The first-of-its-kind cellular immunotherapy uses the patientās immune cells to seek out and kill their cancer
0
0
3
RT @MoffittNews: A first-of-its-kind cellular immunotherapy, #TILTherapy, was pioneered at Moffitt Cancer Center and is now available for pā¦.
0
10
0
RT @MoffittNews: Join Moffitt's President and CEO, @PatrickHwuMD, as he shares insights on the recent @FDA approval of a groundbreaking treā¦.
0
14
0
Apply below!.
APPLY NOW š» If chosen, the Moffitt Innovators of Tomorrow (MIOT) Symposium will provide students a complimentary trip to Tampa, Florida to visit our campus, present their research, meet our faculty and learn about our postdoctoral training opportunities.
0
0
2
RT @JadChahoud: An update with @spt_lab @MoffittResearch @MoffittNews @MoffittGUOnc on the Current State of Cell Therapies for Genitourinarā¦.
pubmed.ncbi.nlm.nih.gov
Genitourinary (GU) cancers have greatly benefited from immunotherapy treatments, such as immune checkpoint inhibitors. However, the durable clinical response rate for these agents remains relatively...
0
1
0
RT @jitcancer: New #JITC hypothesis: Rethinking the immunotherapy numbers game @rebecca_bekker @MohammadUZahid @Jenā¦.
0
10
0